Leading the way
in PD-L1 testing
Introducing the first and only FDA-approved test to assess patients with NSCLC for KEYTRUDA® (pembrolizumab).
Results you can trust
The first and only FDA-approved and
CE-IVD marked PD-L1 test for use in
non-squamous NSCLC for OPDIVO® (nivolumab).
PD-L1 IHC 28-8 pharmDx training
Learn how to evaluate PD-L1 expression in patients with non-squamous NSCLC for OPDIVO® (nivolumab).
See our solutions within pathology, next generation sequencing and molecular cancer research.
2016 Product Catalog
The 2016 Pathology Product Catalog is now available for download.
Events and Congresses
Meet us at congresses and events around the world.